Michael Willem

University Munich
München, Germany

Sabina Tahirovic

DZNE
Munich, Germany

石 一星

Alaa Abou Seoud

CNM
Giza, Egypt

Leslie Norins on Aducanumab Approved to Treat Alzheimer’s Disease

COMMENT As I reviewed these expert reactions to the FDA quasi-approval of aducanumab, I happened to also be reading the best-selling nonfiction book "Empire of Pain" by Patrick Keefe. It explains the machinations of the Sackler family, who took oxyconti

Hanno Roder on Aducanumab Approved to Treat Alzheimer’s Disease

COMMENT I believe this is a terrible decision, probably the worst ever, by the only true policeman we have in the drug-development process. We always believed that clinical trials would be the ultimate arbiters of the avenues elaborated in the labs of scientists.

Hilary Glazer on Aducanumab Approved to Treat Alzheimer’s Disease

COMMENT I have a few questions for the experts here:   1. How do we measure slowing of clinical progression in each patient? Compare to clinical progression in the placebo group of the EMERGE trial? 2. How can the makers of donanemab be encouraged to do a head-to

Jürgen Götz, Rebecca Nisbet on Biogen Shelves Gosuranemab After Negative Alzheimer’s Trial

COMMENT In our view, for a tau antibody to work, there are four major hurdles to overcome: (i) the blood-brain barrier, given that only an estimated 0.1 percent of peripherally administered therapeutic antibodies enter the brain; (ii) the plasma membrane of neuro

Nancy Ip on Stunning Diagnostic Accuracy from a Plasma Protein Panel?

COMMENT We are very grateful for the helpful comments about the development of a blood-based biomarker panel for AD in the present stage. One comment is that clinically diagnosed AD is sometimes mixed with other types of dementia, including frontotemporal dementi

M. Florencia Iulita, Natalia Valle, Olivia Belbin on Neuronal Exosomes Embroiled in Controversy

COMMENT The study of Norman and colleagues is an important contribution toward validating some of the commonly used methodological tools to capture brain-derived extracellular vesicles (EVs), particularly those derived from neurons.   The study focuses on L1CAM,

Ramon Trullas on Neuronal Exosomes Embroiled in Controversy

COMMENT The study by Norman et al. concludes that L1CAM is not associated with extracellular vesicles (EVs) in human plasma or cerebrospinal fluid. The study assumes that all EVs contain tretraspanins, like classical exosomes. However, this assumption is not supp

Yasuo Uchiyama on Post-Golgi carriers, not lysosomes, confer lysosomal properties to pre-degradative organelles in normal and dystrophic axons.

COMMENT Lysosome-related organelles in the axons of intact and dystrophic brains Lysosomes are multifunctional, membrane-bound, acidic organelles that contain various acid hydrolases that degrade excess, old, and unneeded intracellular and extracellular materials

PAPER Waguri S, Dewitte F, Le Borgne R, Rouillé Y, Uchiyama Y, Dubremetz JF, Hoflack B

Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells.

Mol Biol Cell. 2003 Jan;14(1):142-55. PubMed: 12529433

PAPER Koike M, Shibata M, Sunabori T, Yamaguchi J, Sakimura K, Komatsu M, Tanaka K, Uchiyama Y

Purkinje Cells Are More Vulnerable to the Specific Depletion of Cathepsin D Than to That of Atg7.

Am J Pathol. 2017 Jul;187(7):1586-1600. Epub 2017 May 11 PubMed: 28502476

Oleg Butovsky on DAMned to Death? Microglia May Proliferate to Senescence

COMMENT One of the most important questions related to the role of DAM (MGnD) microglia is their contribution to plaque pathology and disease progression in AD. The study by Hu and colleagues is a valuable contribution to our understanding of the role of early de